GWELLA AND THE UNTAPPED OPPORTUNITY IN FUNCTIONAL MUSHROOMS
“Mushrooms can help solve some of the world’s biggest problems.
“They can clean up oil spills, neutralize environmental pollutants and regenerate ecosystems. They can produce biofuel. They can be used to create biodegradable packaging and replace plastic. And they have all sorts of health benefits for humans.”
Peter Reitano, CEO Gwella
Read InterviewLobe Sciences launches preclinical study of psilocybin for brain injury treatment.
ATAI Life Sciences closes US$125 million series C financing round.
Revive Therapeutics partners with PharmaTher for psychedelic cancer research.
Numinus announces compassionate access trial of psilocybin for addiction.
Pure Extracts advances plans for the processing of functional mushroom formulations.
Nova Mentis Life Science completes acquisition of Pilz Bioscience.
Havn Life becomes a voting member of the UK’s Conservative Drug Policy Reform Group.
Entheon Biomedical enters a clinical study agreement for an early phase study on DMT.
Field Trip partners with WHOOP to measure the effectiveness of psychedelic therapies.
NeonMind commences preclinical trial examining psilocybin for weight loss.
PharmaTher partners with UHN to expand digital psychedelic therapeutics platform.
Red Light Holland and Halo Labs announce intention to enter Oregon market.
CaaMTech partners with Leibniz Institute to research psychedelic mushrooms.
ENJOY ACCESS TO EVERY PANEL DISCUSSION FROM THE PSYCH SYMPOSIUM
You can now access every panel discussion that took place during The PSYCH Symposium at Prohibition Partners LIVE, but only a few days remain to catch-up on our programme.
Hear from political, scientific, medical, business and cultural leaders who featured during our online event, here.
Learn MoreOregon starts accepting applications for psilocybin therapy advisory board.
Canadian officials reiterate legal status of psychedelics in decriminalisation petition.
California lawmaker seeks to introduce a psychedelic decriminalisation bill next year.
Advocates push to allow psilocybin therapy for terminally ill patients in Washington.
German government approves MIND Foundation’s psilocybin study.
New Zealand temporarily legalises onsite pill testing ahead of festival season.
New poll finds 64% of Canadians approve of legalising psilocybin for the terminally ill.
New study identifies link between personality traits and psychedelic experiences.
Two studies indicate ketamine may be useful to treat alcohol-use disorder.
San Francisco non-profit launches psychedelic hotline to help navigate experiences.